MIT Submits Application to AOAC for Certification of Test Methods for E. Coli and Salmonella

SAN CLEMENTE, CA--(Marketwire - Feb 7, 2012) - Micro Imaging Technology, Inc. (OTCBB: MMTC) (OTCQB: MMTC) announces the submittal of its applications to the Association of Advanced Communities Research Institute ("AOAC RI") for Performance Test Method Certification for the MIT 1000 System's for accurate bacterial identifications of the pathogens E. coli and Salmonella. In June 2009, MIT announced it was the recipient of the prestigious AOAC RI Certification for the identification of the Listeria bacteria species. Listeria is the bacteria responsible for Listeriosis, a rare but lethal food-borne infection that has a devastating fatality rate of 25 percent. MIT's System, with the two additional pathogenic bacteria identification processes certified, will have the proven capability of identifying over 90 percent of all bacteria causing food related illnesses. The AOAC Report is available from the Company.

The MIT System's identification process is significantly different from all other conventional methods and does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis -- the process is totally green, requiring only clean water and a sample of the unknown bacteria. Importantly, all test procedures for identifying unknown bacteria are identical and can be performed in minutes by a relatively unskilled operator.

The MIT System's uniqueness and the AOAC RI's extensive evaluation criterion required several months of collaboration to agree on a suitable Test Protocol for the Certification for Listeria. After the Test Protocol was complete, MIT and an independent testing laboratory managed by AOAC performed numerous identification and ruggedness tests to determine the efficacy of the MIT 1000 System. The Test Protocol was designed to: 1) Provide independent provability of the accuracy and repeatability of MIT's test method. After numerous tests, this testing phase showed that the accuracy exceeded 98 percent. 2) Test the System's flexibility if procedures employed by the user are varied from the Company's recommendations. A total of 406 ruggedness tests were performed showing a good tolerance to sensible variations in Company recommend procedures. The preparation of a Final Report in an AOAC RI's format was then submitted to their independent expert reviewers.

David Haavig, PhD and MIT's Chief Scientist, stated, "The AOAC Certification process for E. coli and Salmonella, following this application, should only require three or four months. Since the protocol for making test samples and also the procedure and software for testing using the MIT 1000 are identical to that of Listeria, the time required for AOAC RI to develop the E. coli and Salmonella Certification Test Protocol should be substantially reduced."

"The food industry is our initial targeted market where over $5 billion is spent in rapid ID testing annually and rising in excess of 9 percent per year -- which should accelerate after all the recent food product contamination disclosures and federal legislative actions. Further, it is noteworthy that MIT has demonstrated, without any modifications to testing procedures, the ability to ID, within several minutes and at a cost of pennies per test, over twenty different species of bacteria including the microbes E.coli, Listeria, Salmonella, Staphylococcus aureus, MRSA and other pathogenic bacteria," stated Michael Brennan, MIT's Chairman.

About AOAC International and AOAC Research Institute:

AOAC International is a globally recognized, independent, not-for-profit association founded in 1884. To attain its vision of "worldwide confidence in analytical results," AOAC serves communities of the analytical sciences by providing the tools and processes necessary to develop voluntary consensus standards or technical standards through stakeholder consensus and working groups in which the fit-for-purpose and method performance criteria are established and fully documented. The AOAC Research Institute is part of AOAC International and maintains an up-to-the minute list of Performance Tested Methods which have been independently tested, rigorously evaluated and thoroughly reviewed by the AOAC Research Institute and its expert reviewers.

About Micro Imaging Technology:

MIT is a California-based public company (OTCBB: MMTC) that has developed and patented a rapid microbial identification system that can revolutionize the bacteria identification market by annually saving thousands of lives and tens of millions of dollars. The System identifies bacteria in minutes, not days, and at a significant per test cost savings when compared to any conventional method.

The System is laser and optically based using the proven principles of applied physics in conjunction with proprietary PC-based software algorithms. MIT, through independent testing has proven the ability, with high accuracy and in minutes, to identify the most dangerous and pervasive pathogens; E. coli, Listeria, Salmonella, Staphylococcus aureus and MRSA.

The System has numerous applications including: food safety, clinical diagnostics, pharmaceutical quality assurance, semiconductor processing control and water quality monitoring. MIT has chosen to focus initial efforts on food quality control as recent events have created an urgent demand for quicker and cheaper testing for food safety.

Earlier, MIT also contracted with North American Science Associates, Inc. ("NAMSA") an internationally recognized testing laboratory to design and perform a verification test that compared the speed, accuracy and efficiency of MIT's System with conventional processes. The comparative tests were in a double blind experiment, meaning that the NAMSA laboratory technicians, using the MIT System and a well recognized alternative, were not aware of the identity of the various microbes. The MIT system scored 98 percent correct identifications in fifty tests, with each test consuming several minutes for sample preparation and an average three minutes for testing. The alternative system was correct 80 percent and failed to identify, with several attempts, one pathogenic bacterium and took hours per test with the alternative biological testing method requiring days. The NAMSA Report is available from the Company.

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission.